CryoPort

CYRX

Market cap $516M

Cryoport receives a buy rating with a $9.1 price target, implying 17% upside by FY 2026. CYRX demonstrated double-digit revenue growth in Q4 2025, led by Life Sciences Services, and improved gross margins to 47.8%. Management targets positive adjusted EBITDA in H2 2026, supported by cost reductions and a strengthened partnership with DHL.

Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.42 per share a year ago.

FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025 Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025 Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y) NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its fourth quarter (Q4) and year ended (FY) December 31, 2025.

NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close.

Self-Sustaining Fusion® 800 Series  Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced the launch of the MVE Fusion® 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology.

Cryoport, Inc. (CYRX) is the leading provider of temperature-controlled supply chain solutions for the rapidly growing cell and gene therapy industry. CYRX supports 745 clinical trials and 19 commercial therapies, with commercial segment revenue up 36% YoY, reflecting accelerating industry adoption. Despite strong growth and a dominant market position, CYRX trades at depressed valuations, offering a deep value opportunity for patient investors.

Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World

Cryoport, Inc. ( CYRX ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Jerrell Shelton - Chairman, President & CEO Robert Stefanovich - Senior VP, CFO, Treasurer & Chief Administrative Officer Mark W. Sawicki - Senior VP & Chief Scientific Officer Thomas Heinzen - Vice President of Corporate Development & Investor Relations Conference Call Participants Todd Fromer - Kanan, Corbin, Schupak & Aronow, Inc. Kyle Crews - UBS Investment Bank, Research Division David Saxon - Needham & Company, LLC, Research Division Puneet Souda - Leerink Partners LLC, Research Division Matthew Stanton - Jefferies LLC, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division David Larsen - BTIG, LLC, Research Division Mason Carrico - Stephens Inc., Research Division Presentation Operator " Jerrell Shelton Chairman, President & CEO " Robert Stefanovich Senior VP, CFO, Treasurer & Chief Administrative Officer " Mark W.

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.02 per share a year ago.